Ritter Pharmaceuticals Inc (NASDAQ:RTTR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Tuesday.

According to Zacks, “Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. “

Separately, Maxim Group lowered their price target on shares of Ritter Pharmaceuticals from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Monday, August 15th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/ritter-pharmaceuticals-inc-rttr-raised-to-hold-at-zacks-investment-research.html

Ritter Pharmaceuticals (NASDAQ:RTTR) traded up 2.84% during mid-day trading on Tuesday, hitting $1.45. 83,556 shares of the stock were exchanged. Ritter Pharmaceuticals has a 12-month low of $0.98 and a 12-month high of $3.13. The firm’s market cap is $12.45 million. The company has a 50 day moving average of $1.34 and a 200 day moving average of $1.49.

Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its quarterly earnings results on Monday, August 8th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.14. On average, equities analysts anticipate that Ritter Pharmaceuticals will post ($1.38) earnings per share for the current fiscal year.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

5 Day Chart for NASDAQ:RTTR

Get a free copy of the Zacks research report on Ritter Pharmaceuticals (RTTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ritter Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.